Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edward Paule who wrote (10038)	5/17/1999 10:55:00 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

You mean rBPI21 might have some antiendotoxin properties BESIDES possible antibacterial affects against gram neg beasties?<g> Study the role of LBP and patents regarding it. Is there a way to make LBP that won't kick off CD14 and if so who has patents covering it?<g>

To: Edward Paule who wrote (10038)	5/17/1999 3:07:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

Edward, you are right the lps is decreased, but how much is "free" vs bound to rBPI21 ? And let's add CLEARANCE of lps is faster and more efficient with rBPI21. I have being looking for the full article on this baboon beastness and BPI. Not at hand yet. I did noticed the emphasis on antibacterial vs antiendotoxin, I think the final wording of the abstract is misleading at best, wrong at worst. But will reserve my final judgement for the time that I have the full article at hand. If Bpi is not an inflammatory cascade regulator (besides its potent antibacterial effect), I will put all my money out right now. Just killing bacteria is dumb bomb. Many times there are no bacteria growing in blood and patients are "sterile" but the shock continues the same.